首页> 美国卫生研究院文献>Scientific Reports >Evolutionary analysis of human parechovirus type 3 and clinical outcomes of infection during the 2017–18 Australian epidemic
【2h】

Evolutionary analysis of human parechovirus type 3 and clinical outcomes of infection during the 2017–18 Australian epidemic

机译:2017-18年度澳大利亚流行期间人类3型副腮病毒和感染临床结局的进化分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human parechovirus type 3 (HPeV3) can cause severe sepsis-like illness in young infants and may be associated with long term neurodevelopmental delay later in childhood. We investigated the molecular epidemiology of HPeV infection in thirty three infants requiring hospitalization before, during and after the peak of the 2017/18 HPeV epidemic wave in Australia. During the peak of the epidemic, all cases were infected with an HPeV3, while before and after the peak, HPeV1 was the predominant type detected. The predominant HPeV3 was the recombinant HPeV3 also detected in the 2013/14 and 2015/16 Australian epidemics. Sepsis-like or meningitis-like symptoms were only reported in cases infected with the recombinant HPeV3. Phylogenetic analysis of the recombinant HPeV3 revealed that the virus continued to evolve, also between the Australian outbreaks, thus indicating continued circulation, despite not being detected and reported in Australia or elsewhere in between epidemic waves. The recombinant HPeV3 continued to show a remarkable stability in its capsid amino acid sequence, further strengthening our previous argument for development of a vaccine or immunotherapeutics to reduce the severity of HPeV3 outbreaks due to this virus.
机译:人类3型副腮病毒(HPeV3)可以在婴儿中引起严重的败血症样疾病,并且可能与儿童后期的长期神经发育迟缓有关。我们调查了澳大利亚2017/18年HPeV流行病波高峰之前,之中和之后需要住院的33例婴儿中HPeV感染的分子流行病学。在流行高峰期间,所有病例均感染了HPeV3,而在高峰前后,HPeV1是检出的主要类型。主要的HPeV3是在2013/14和2015/16澳大利亚流行病中也检测到的重组HPeV3。仅在感染重组HPeV3的病例中报告了败血症样或脑膜炎样症状。重组HPeV3的系统发育分析表明,该病毒还在澳大利亚爆发之间继续进化,尽管在澳大利亚或其他流行病之间没有发现和报告过这种病毒,但表明病毒仍在继续传播。重组HPeV3的衣壳氨基酸序列继续显示出显着的稳定性,进一步加强了我们先前关于开发疫苗或免疫疗法以减少由该病毒引起的HPeV3爆发的严重性的论点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号